May 31 (Reuters) - Bristol-Myers Squibb Co :
* CEO says company will not "downsize" research and development, but adjust it in accordance with ongoing performance of company
* CEO says biggest mid-term company focus will be on oncology, virology, anti-coagulation
* CEO says Gilead and Bristol should combine their respective experimental medicines for hepatitis c in late-stage trials
* CEO says he suspects Gilead would prefer instead to first explore combinations of gilead's own hepatitis c medicines
* CEO says expects some form of subsequent healthcare reform even if supreme court shoots down health care law
* CEO says U.S. healthcare reform started on right foot, but then became too complicated for drugmakers and American people
* CEO says significant future company sales growth will come from Asia, not from Europe
((New York Equities Desk; tel: +1 646 223 6000))
((For more news about Bristol-Myers Squibb Co click here: ))
(C) Reuters 2012. All rights reserved. Republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters.
No comments:
Post a Comment